Hello, everyone, and how are you this morning? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the leafy Pharmalot campus. Our short people have left for their destinations, our official mascot has tired himself out and is now snoozing in a corner, and we are left with a beckoning coffee pot that is waiting to be fired up. And so, on with the show. Here are a few tidbits to help on your journey. We hope your day is productive and also meaningful. Why not add a little zen now and then? Good luck and keep in touch. …

The Food and Drug Administration approved a medicine from Jacobus Pharmaceuticals, a small, family-run company, for treating a neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS, for children ages 6 to 17, STAT reports. The move potentially adds unforeseen competition for Catalyst Pharmaceuticals (CPRX), which last December won an FDA endorsement to market a treatment for adults. The approval adds an unexpected twist to a simmering controversy over a rare disease drug that briefly became a poster child for high-priced medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy